tradmap

IRLA Earnings IRulya Therapeutics Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$606 -$303 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$90M -$45M $0 2018 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-189% 23% 235% 0% 2018 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$149 -$46 $58 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Net income (quarterly)
-$75M -$20M $36M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-1269% -520% 229% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–25 of 25
Q2 20262026-06-30-12.312026-08-1410-Q
Q1 20262026-03-3157.602026-05-1110-Q
Q4 2025 (derived)2025-12-31-148.852026-04-1010-K
FY 20252025-12-31-336.002026-04-1010-K
Q3 20252025-09-30-50.002025-11-1210-Q
Q2 20252025-06-30-68.752025-08-1110-Q
Q1 20252025-03-31-68.402025-05-1310-Q
Q4 2024 (derived)2024-12-31-56.002025-03-2410-K
FY 20242024-12-31-262.002025-03-2410-K
Q3 20242024-09-30-26.002024-11-1310-Q
Q2 20242024-06-30-128.002024-08-1310-Q
Q1 20242024-03-31-52.002024-05-1310-Q
Q4 2023 (derived)2023-12-31-42.002024-04-0110-K
FY 20232023-12-31-168.002024-04-0110-K
Q3 20232023-09-30-30.002023-11-1410-Q
Q2 20232023-06-30-28.002023-08-0310-Q
Q1 20232023-03-31-68.002023-05-1510-Q
Q4 2022 (derived)2022-12-31-18.002023-03-1510-K
FY 20222022-12-31-308.002023-03-1510-K
Q3 20222022-09-30-44.002022-11-0910-Q
Q2 20222022-06-30-102.002022-08-0910-Q
Q1 20222022-03-31-144.00——
FY 20212021-12-31-606.00——
Q3 20212021-09-30-146.00——
Q2 20212021-06-30-148.00——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.